NASDAQ:ELOX Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis $0.13 0.00 (0.00%) As of 05/7/2026 11:06 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.13▼$0.1350-Day Range$0.00▼$0.1952-Week Range$0.00▼$0.75Volume698 shsAverage Volume13,098 shsMarket Capitalization$659.87 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) is a clinical‐stage biopharmaceutical company focused on developing precision medicines for rare genetic diseases caused by nonsense mutations. Its lead candidate, ELX-02, is a novel small molecule designed to enable ribosomal read-through of premature stop codons and restore production of full-length, functional proteins. The company’s initial therapeutic targets include cystic fibrosis and cystinosis, with ELX-02 advancing through Phase 2 clinical studies in cystic fibrosis and Phase 1/2 trials in cystinosis. In addition to ELX-02, Eloxx is advancing second-generation read-through compounds in its discovery pipeline to broaden treatment opportunities for patients with other nonsense mutation-driven disorders. The company’s research and development efforts leverage proprietary chemistry to optimize efficacy and safety profiles, and it has established clinical sites across North America and Europe to support multi-regional trials. Eloxx aims to address a high unmet medical need by providing targeted therapies where few or no approved options exist. Founded in 2016 and incorporated in Delaware, Eloxx Pharmaceuticals is headquartered in Mamaroneck, New York. The company’s management team includes seasoned biotechnology executives with deep expertise in rare disease drug development, clinical operations and regulatory affairs. Eloxx is committed to advancing its pipeline through clinical milestones and to forging strategic collaborations that can accelerate development timelines and expand patient access worldwide.AI Generated. May Contain Errors. Read More Receive ELOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOX Stock News HeadlinesEloxx Pharmaceuticals Delays Form 10-Q FilingAugust 15, 2025 | msn.comEloxx Pharmaceuticals Announces Key Corporate AccomplishmentsNovember 12, 2024 | tmcnet.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker. | Paradigm Press (Ad)Eloxx Pharmaceuticals (OTC:ELOX) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comEloxx Pharmaceuticals Provides Pipeline and Financing UpdatesJuly 11, 2024 | globenewswire.comEloxx Pharmaceuticals Inc (ELOX)April 24, 2024 | investing.comDelveInsight Business Research, LLP: Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 17, 2024 | finanznachrichten.deAlport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsightApril 17, 2024 | finance.yahoo.comSee More Headlines ELOX Stock Analysis - Frequently Asked Questions How have ELOX shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0001 at the start of the year. Since then, ELOX shares have increased by 130,000.0% and is now trading at $0.1301. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) posted its quarterly earnings data on Monday, April, 3rd. The company reported ($2.92) earnings per share for the quarter, topping analysts' consensus estimates of ($2.97) by $0.05. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eloxx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eloxx Pharmaceuticals investors own include Tesla (TSLA), ADMA Biologics (ADMA), Adverum Biotechnologies (ADVM), Assertio (ASRT), Fulcrum Therapeutics (FULC), Akebia Therapeutics (AKBA). Company Calendar Last Earnings4/03/2023Today5/08/2026Next Earnings (Estimated)5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone(781) 577-5300Fax908-864-4440Employees30Year Founded2013Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,072,000Free Float2,508,000Market Cap$659.87 thousand OptionableNot Optionable Beta-1,907.33 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ELOX) was last updated on 5/9/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
